The AI-based chatbot ChatGPT, which drove everyone insane with its ability to create human-like responses when prompted, has now achieved a new milestone in medical science as well! Researchers have found that it can help doctors detect the early stages of Alzheimer's disease.&nbsp;

A study from the Philadelphia-based Drexel University School of Biomedical Engineering, Science and Health Systems found Open AI's ChatGPT was 80 per cent accurate in predicting early signs of dementia.

Also Read |&nbsp;<a href="https://www.wionews.com/science/scientists-create-a-knife-that-can-smell-tumours-and-detects-womb-cancer-in-seconds-549264">Study shows knife that can ‘smell tumours’, detects womb cancer ‘in seconds’: Here's how it works</a>

The study's authors write in their peer-reviewed paper, published on Dec. 22 in the journal PLOS Digital Health, that the program offers a "promising approach" to assessing Alzheimer's disease. 
"Our proof-of-concept shows that this could be a simple, accessible and adequately sensitive tool for community-based testing," Hualou Liang, a Drexel professor and co-author of the study, said in a news release.

"This could be very useful for early screening and risk assessment before a clinical diagnosis."

Researchers behind the ChatGPT study say because language impairment affects between 60 and 80 per cent of dementia patients, programs that can detect "subtle clues," such as grammar and pronunciation mistakes, hesitation, and forgetting the meaning of words, could help determine whether a patient needs a full examination. Although there is no cure for Alzheimer's, researchers say therapeutic options exist if the disease is spotted early.

"The most commonly used tests for early detection of Alzheimer's look at acoustic features, such as pausing, articulation and vocal quality, in addition to tests of cognition," Liang said. "But we believe the improvement of natural language processing programs provides another path to support early identification of Alzheimer's."

Watch |&nbsp;Lensa-AI pictures swarm social media

<div class="ui-state-default" contenteditable="false">
<div class="twitter-block" draggable="false">
<div class="videoWrapper trancodeVideo"><iframe allowfullscreen="" autoplay="1" class="includeVideo" frameborder="0" height="350" src="https://www.wionews.com/videos/gravitas-lensa-ai-pictures-swarm-social-media-542816/embed" style="width:100%;max-width:560px;" width="560"></iframe></div>
</div>
<a class="close-mark close-div" href="#" id="jqclosemark">×</a></div>

The programme also outperformed an "acoustic" analysis that only&nbsp;looked at features like pauses, voice strength, and slurring in predicting the severity of a person's dementia.

Felix Agbavor, a doctoral researcher and the paper's lead author, said training ChatGPT with a "massive dataset of interviews," including some with Alzheimer's patients, would provide the information needed to detect speech patterns that could then identify future patients. Moving forward, the researchers plan to develop a web app that could be used as a pre-screening tool for Alzheimer's at home or in a doctor's office.

ChatGPT gained widespread attention after OpenAI made the AI-powered chatbot available for public testing, fascinating users with its ability to respond to a variety of questions.

&nbsp;

WATCH WION LIVE HERE

<iframe allow="accelerometer; autoplay; encrypted-media; gyroscope; picture-in-picture" allowfullscreen="" frameborder="0" height="350" loading="”lazy”" src="https://www.wionews.com/live-tv/embed?autoplay=1&amp;mute=1" width="100%"></iframe>

You can now write for wionews.com and be a part of the community. Share your stories and opinions with us <a href="https://www.wionews.com/content-contribution-registration-form">here</a>.

The AI-based chatbot ChatGPT, which drove everyone insane with its ability to create human-like responses when prompted, has now achieved a new milestone in medical science as well!

The AI-based chatbot ChatGPT, which drove everyone insane with its ability to create human-like responses when prompted, has now achieved a new milestone in medical science as well! Researchers have found that it can help doctors detect the early stages of Alzheimer's disease. A study from the Philadelphia-based Drexel University School of Biomedical Engineering, Science and Health Systems found Open AI's ChatGPT was 80 per cent accurate in predicting early signs of dementia. Also Read | Study shows knife that can ‘smell tumours’, detects womb cancer ‘in seconds’: Here's how it works The study's authors write in their peer-reviewed paper, published on Dec. 22 in the journal PLOS Digital Health, that the program offers a "promising approach" to assessing Alzheimer's disease. "Our proof-of-concept shows that this could be a simple, accessible and adequately sensitive tool for community-based testing," Hualou Liang, a Drexel professor and co-author of the study, said in a news release. "This could be very useful for early screening and risk assessment before a clinical diagnosis." Researchers behind the ChatGPT study say because language impairment affects between 60 and 80 per cent of dementia patients, programs that can detect "subtle clues," such as grammar and pronunciation mistakes, hesitation, and forgetting the meaning of words, could help determine whether a patient needs a full examination. Although there is no cure for Alzheimer's, researchers say therapeutic options exist if the disease is spotted early. "The most commonly used tests for early detection of Alzheimer's look at acoustic features, such as pausing, articulation and vocal quality, in addition to tests of cognition," Liang said. "But we believe the improvement of natural language processing programs provides another path to support early identification of Alzheimer's." Watch | Lensa-AI pictures swarm social media × The programme also outperformed an "acoustic" analysis that only looked at features like pauses, voice strength, and slurring in predicting the severity of a person's dementia. Felix Agbavor, a doctoral researcher and the paper's lead author, said training ChatGPT with a "massive dataset of interviews," including some with Alzheimer's patients, would provide the information needed to detect speech patterns that could then identify future patients. Moving forward, the researchers plan to develop a web app that could be used as a pre-screening tool for Alzheimer's at home or in a doctor's office. ChatGPT gained widespread attention after OpenAI made the AI-powered chatbot available for public testing, fascinating users with its ability to respond to a variety of questions. WATCH WION LIVE HERE You can now write for wionews.com and be a part of the community. Share your stories and opinions with us here.

AI-powered chatbot, ChatGPT can help detect early stages of Alzheimer's disease: Study

An experimental drug, lecanemab, is being hailed as a breakthrough in&nbsp;Alzheimer's therapy&nbsp;after a clinical trial confirms that it slows the progression of cognitive decline in patients with early stages of the disease. However, a detailed report of the findings&nbsp; published&nbsp;on Tuesday&nbsp;showed&nbsp;serious side effects that certain patients that took the drug suffered, the discussion of which&nbsp;is now at the forefront.&nbsp;

The findings were published in the New England Journal of Medicine and subsequently presented at the Clinical Trials on Alzheimer's Disease meeting in San Francisco, on Tuesday.&nbsp;This comes nearly two months after the Japan-based&nbsp;Eisai and American company Biogen, the developers of lecanemab, said it showed huge potential and slowed down cognitive and functional decline by almost 27 per cent over 18 months.&nbsp;

ALSO READ |&nbsp;<a href="https://www.wionews.com/world/medical-breakthrough-experimental-alzheimers-drug-slows-cognitive-decline-by-27-per-cent-in-trial-520445">Medical breakthrough? Experimental Alzheimer's drug slows cognitive decline by 27 per cent</a>

The drug was tested on nearly 18,000 participants with early-stage Alzheimer's, while Phase 2, which lasted for a year, did not show a significant difference between patients who received a&nbsp;lecanemab as opposed to a placebo and it was not until Phase 3 that a&nbsp;slowed-down progression was not noted.&nbsp;

Phase 3 trials were conducted in over 230 locations across North America, Europe and Asia between 2019 to 2021 with participants aged from 50 to 90, who suffered from mild cognitive impairment due to early Alzheimer's. At least half of the patients, chosen at random were given lecanemab while others received a placebo.&nbsp;

Subsequently, at&nbsp;least 13 per cent of patients reported dangerous brain swelling and others reported bleeding in the brain during the Phase 3 trials. Furthermore, at least five participants suffered macrohemorrhages and 14 per cent suffered from microhemorrhages, both of which were linked to the drug.&nbsp;

ALSO WATCH |&nbsp;<a href="https://www.wionews.com/videos/gravitas-studies-show-that-poor-sleep-can-cause-alzheimers-497457">Gravitas: Studies show that poor sleep can cause Alzheimer's</a>

However, the US-based Alzheimer’s Association welcomed the results, in a statement that said, “Treatments that deliver tangible benefits to those living with mild cognitive impairment (MCI) due to Alzheimer’s and early Alzheimer’s dementia are as valuable as treatments that extend the lives of those with other terminal diseases.”&nbsp;

Lecanemab is said to be an antibody therapy which removes beta-amyloid which are clumps of protein building up in the brain. While it has not been determined how much of this build-up leads to Alzheimer’s in patients, it does indicate how the brain changes due to this&nbsp;and eventually destroys brain cells.&nbsp;

ALSO READ |&nbsp;<a href="https://www.wionews.com/entertainment/lifestyle/news-world-alzheimers-day-expert-tells-wion-how-to-take-care-of-alzheimers-patient-at-home-518411">World Alzheimer's Day: Expert tells WION how to take care of Alzheimer's patient at home</a>

Notably, over the span of 18 months, 68 per cent of the participants who took the drug had amyloid clearance as well as lower levels of a different protein, tau, that forms toxic tangles inside brain cells, said the Japanese drugmaker. In an interview with Reuters, Ivan Cheung, Eisai's US chairman&nbsp;said the two deaths caused by brain haemorrhages “cannot be attributed to lecanemab.”&nbsp;

Referring to the two participants, where a 65-year-old woman was on medication for clearing blood clots after suffering a stroke and an 87-year-old who was on a blood thinner drug called Eliquis. Eisai said that the company had protocols in place for monitoring brain swelling in participants but sees no need for restrictions on which patients might be eligible for the Alzheimer's drug.&nbsp;

(With inputs from agencies)&nbsp;

WATCH WION LIVE HERE

<iframe allow="accelerometer; autoplay; encrypted-media; gyroscope; picture-in-picture" allowfullscreen="" frameborder="0" height="350" loading="”lazy”" src="https://www.wionews.com/live-tv/embed?autoplay=1&amp;mute=1" width="100%"></iframe>

You can now write for wionews.com and be a part of the community. Share your stories and opinions with us <a href="https://www.wionews.com/content-contribution-registration-form">here</a>.

An experimental drug, lecanemab, is being hailed as a breakthrough in Alzheimer's therapy after a clinical trial confirms that it slows the progression of cognitive decline in patients with early stages of the disease.

An experimental drug, lecanemab, is being hailed as a breakthrough in Alzheimer's therapy after a clinical trial confirms that it slows the progression of cognitive decline in patients with early stages of the disease. However, a detailed report of the findings published on Tuesday showed serious side effects that certain patients that took the drug suffered, the discussion of which is now at the forefront. The findings were published in the New England Journal of Medicine and subsequently presented at the Clinical Trials on Alzheimer's Disease meeting in San Francisco, on Tuesday. This comes nearly two months after the Japan-based Eisai and American company Biogen, the developers of lecanemab, said it showed huge potential and slowed down cognitive and functional decline by almost 27 per cent over 18 months. ALSO READ | Medical breakthrough? Experimental Alzheimer's drug slows cognitive decline by 27 per cent The drug was tested on nearly 18,000 participants with early-stage Alzheimer's, while Phase 2, which lasted for a year, did not show a significant difference between patients who received a lecanemab as opposed to a placebo and it was not until Phase 3 that a slowed-down progression was not noted. Phase 3 trials were conducted in over 230 locations across North America, Europe and Asia between 2019 to 2021 with participants aged from 50 to 90, who suffered from mild cognitive impairment due to early Alzheimer's. At least half of the patients, chosen at random were given lecanemab while others received a placebo. Subsequently, at least 13 per cent of patients reported dangerous brain swelling and others reported bleeding in the brain during the Phase 3 trials. Furthermore, at least five participants suffered macrohemorrhages and 14 per cent suffered from microhemorrhages, both of which were linked to the drug. ALSO WATCH | Gravitas: Studies show that poor sleep can cause Alzheimer's However, the US-based Alzheimer’s Association welcomed the results, in a statement that said, “Treatments that deliver tangible benefits to those living with mild cognitive impairment (MCI) due to Alzheimer’s and early Alzheimer’s dementia are as valuable as treatments that extend the lives of those with other terminal diseases.” Lecanemab is said to be an antibody therapy which removes beta-amyloid which are clumps of protein building up in the brain. While it has not been determined how much of this build-up leads to Alzheimer’s in patients, it does indicate how the brain changes due to this and eventually destroys brain cells. ALSO READ | World Alzheimer's Day: Expert tells WION how to take care of Alzheimer's patient at home Notably, over the span of 18 months, 68 per cent of the participants who took the drug had amyloid clearance as well as lower levels of a different protein, tau, that forms toxic tangles inside brain cells, said the Japanese drugmaker. In an interview with Reuters, Ivan Cheung, Eisai's US chairman said the two deaths caused by brain haemorrhages “cannot be attributed to lecanemab.” Referring to the two participants, where a 65-year-old woman was on medication for clearing blood clots after suffering a stroke and an 87-year-old who was on a blood thinner drug called Eliquis. Eisai said that the company had protocols in place for monitoring brain swelling in participants but sees no need for restrictions on which patients might be eligible for the Alzheimer's drug. (With inputs from agencies) WATCH WION LIVE HERE You can now write for wionews.com and be a part of the community. Share your stories and opinions with us here.

Experimental drug slows down cognitive decline in Alzheimer's patients: Here’s what you need to know

Did you know that certain genes make you more likely to develop Alzheimer's disease?&nbsp;Other risk factors include lifestyle, age and environment.

If you aren't living under a rock, you must have heard of Hollywood star Chris Hemsworth taking a break from acting over Alzheimer's risk. While shooting his docuseries 'Limitless', the 39-year-old actor got to know that he is eight to ten times more&nbsp;likely than an average person to battle the progressive disease and that has a lot to do with his genes.&nbsp;

After meeting physician Dr Peter Attia, he underwent a series of genetic tests and discovered that his DNA carries two copies of the APOE4 gene. A set from his mom and a set from his dad.

For those uninitiated, the APOE4 gene has the strongest correlation to the development of Alzheimer’s disease. And, according to a study, inheriting a single copy of APOE4 raises the risk of developing Alzheimer's about 3-fold and having two copies raises the risk to about 8 to 12-fold.

Several pieces of research on the progressive neurodegenerative disorder, which is the most common cause of dementia, have identified a number of genes associated with the disease. While risk genes increase your likelihood of developing the disease. Deterministic genes guarantee that you will develop the disease, though these are rare.

Also read:&nbsp;<a data-ved="2ahUKEwihnPqrsMH7AhXFVHwKHcetBmMQFnoECBAQAQ" href="https://www.wionews.com/entertainment/lifestyle/news-expert-talk-doctor-reveals-how-sedentary-lifestyle-leads-to-cardiac-ailments-521168" ping="/url?sa=t&amp;source=web&amp;rct=j&amp;url=https://www.wionews.com/entertainment/lifestyle/news-expert-talk-doctor-reveals-how-sedentary-lifestyle-leads-to-cardiac-ailments-521168&amp;ved=2ahUKEwihnPqrsMH7AhXFVHwKHcetBmMQFnoECBAQAQ">Doctor reveals how sedentary lifestyle leads to cardiac ailments</a>

The Apolipoprotein E (APOE) risk gene is the&nbsp;most common gene associated with late-onset Alzheimer's disease and it has three common forms. The least common form is APOE e2, which reduces the risk of Alzheimer's. The second form is APOE e4, which increases the risk of Alzheimer's and is associated with getting the disease at an earlier age. The third and last form is APOE e3, which doesn't seem to affect the risk of Alzheimer's.

But you must remember that not everyone who has one or even two APOE4 genes develops Alzheimer's disease. And, the disease can also occur in people who don't have an APOE4 gene.&nbsp;Several other genetic and environmental factors are involved in the development of the progressive neurologic disorder.

To find out whether you have this gene in your DNA, you can opt for genetic testing for AD. With a single blood test, doctors can identify which APOE alleles a person has, but, you must remember that the results cannot predict who will or will not develop the disease.

Before being tested, we suggest that you weigh the emotional consequences of having such information. And, the results can affect your eligibility for some forms of insurance, long-term care, disability and life insurance.

Disclaimer: The medical information in this article is not a substitute for expert opinion or doctor's advice. Please consult a doctor for an accurate diagnosis.

WATCH WION LIVE HERE

<iframe allow="accelerometer; autoplay; encrypted-media; gyroscope; picture-in-picture" allowfullscreen="" frameborder="0" height="350" loading="”lazy”" src="https://www.wionews.com/live-tv/embed?autoplay=1&amp;mute=1" width="100%"></iframe>

You can now write for wionews.com and be a part of the community. Share your stories and opinions with us <a href="https://www.wionews.com/content-contribution-registration-form">here</a>.

Did you know that certain genes make you more likely to develop Alzheimer's disease? Other risk factors include lifestyle, age and environment. If you aren't living under a rock, you must have heard of Hollywood star Chris Hemsworth taking a break from acting over Alzheimer's risk.

Did you know that certain genes make you more likely to develop Alzheimer's disease? Other risk factors include lifestyle, age and environment. If you aren't living under a rock, you must have heard of Hollywood star Chris Hemsworth taking a break from acting over Alzheimer's risk. While shooting his docuseries 'Limitless', the 39-year-old actor got to know that he is eight to ten times more likely than an average person to battle the progressive disease and that has a lot to do with his genes. After meeting physician Dr Peter Attia, he underwent a series of genetic tests and discovered that his DNA carries two copies of the APOE4 gene. A set from his mom and a set from his dad. For those uninitiated, the APOE4 gene has the strongest correlation to the development of Alzheimer’s disease. And, according to a study, inheriting a single copy of APOE4 raises the risk of developing Alzheimer's about 3-fold and having two copies raises the risk to about 8 to 12-fold. Several pieces of research on the progressive neurodegenerative disorder, which is the most common cause of dementia, have identified a number of genes associated with the disease. While risk genes increase your likelihood of developing the disease. Deterministic genes guarantee that you will develop the disease, though these are rare. Also read: Doctor reveals how sedentary lifestyle leads to cardiac ailments The Apolipoprotein E (APOE) risk gene is the most common gene associated with late-onset Alzheimer's disease and it has three common forms. The least common form is APOE e2, which reduces the risk of Alzheimer's. The second form is APOE e4, which increases the risk of Alzheimer's and is associated with getting the disease at an earlier age. The third and last form is APOE e3, which doesn't seem to affect the risk of Alzheimer's. But you must remember that not everyone who has one or even two APOE4 genes develops Alzheimer's disease. And, the disease can also occur in people who don't have an APOE4 gene. Several other genetic and environmental factors are involved in the development of the progressive neurologic disorder. To find out whether you have this gene in your DNA, you can opt for genetic testing for AD. With a single blood test, doctors can identify which APOE alleles a person has, but, you must remember that the results cannot predict who will or will not develop the disease. Before being tested, we suggest that you weigh the emotional consequences of having such information. And, the results can affect your eligibility for some forms of insurance, long-term care, disability and life insurance. Disclaimer: The medical information in this article is not a substitute for expert opinion or doctor's advice. Please consult a doctor for an accurate diagnosis. WATCH WION LIVE HERE You can now write for wionews.com and be a part of the community. Share your stories and opinions with us here.

Chris Hemsworth pauses career due to Alzheimer's risk. Here's how to find out if you're at risk